Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cybin ( (TSE:CYBN) ) has shared an update.
Cybin announced that its Chief Medical Officer, Amir Inamdar, will participate in a fireside chat at the Cantor Global Healthcare Conference 2025. This participation highlights Cybin’s ongoing efforts to engage with the healthcare community and stakeholders, potentially impacting its industry positioning and showcasing its advancements in mental health treatments.
The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$39.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.
Spark’s Take on TSE:CYBN Stock
According to Spark, TipRanks’ AI Analyst, TSE:CYBN is a Underperform.
Cybin’s stock score is significantly impacted by its lack of revenue and continuous financial losses, resulting in a low valuation score. While technical indicators are neutral, positive corporate events indicate potential for future growth. However, current financial challenges remain the dominant concern.
To see Spark’s full report on TSE:CYBN stock, click here.
More about Cybin
Cybin is a clinical-stage neuropsychiatry company focused on revolutionizing mental healthcare by developing innovative next-generation treatment options. The company is working on novel drugs like CYB003 and CYB004 for treating major depressive disorder and generalized anxiety disorder, respectively. Founded in 2019, Cybin operates in Canada, the United States, the United Kingdom, and Ireland.
Technical Sentiment Signal: Hold
Current Market Cap: C$1.97M
See more data about CYBN stock on TipRanks’ Stock Analysis page.